目的探讨坦索罗辛联合托特罗定用于行经尿道前列腺电切术的高危前列腺增生患者的围手术期临床效果和安全性。方法 2011年4月至2014年2月本院就诊的行经尿道前列腺电切术的高危前列腺增生患者共99例,分入组1(联用坦索罗辛和托特罗定,35例)、组2(服用坦索罗辛,20例)和组3(未服用坦索罗辛或托特罗定,44例)。比较各组术后住院天数,术后膀胱痉挛发生率、持续天数和日发生次数,拔尿管后急迫性尿失禁发生率、持续天数和日发生次数。结果 99例患者手术均成功,无严重出血、膀胱穿孔和前列腺电切综合征等明显并发症。术后住院天数,组1、组2和组3分别为(8.8±2.0)、(10.2±2.5)和(10.4±2.5)d,组1显著短于组2和组3,差异具有统计学意义(P=0.011);拔管后急迫性尿失禁持续时间和日发生次数,组1<组2和组3(P<0.05);术后膀胱痉挛发生率组1、组2和组3分别为68.6%、95.0%和90.9%,组1明显低于组2和组3(P=0.009);膀胱痉挛持续时间及日发生次数组1也小于组2和组3(P<0.05)。结论坦索罗辛联合托特罗定用于行经尿道前列腺电切术的高危前列腺增生患者安全有效,能促进患者恢复,并且可以减少术后膀胱痉挛的发生。 Objective To investigate the perioperative efficacy and safety of tamsulosin plus tolterodine in high-risk patients with benign prostatic hyperplasia (BPH) undergoing transurethral resection of the prostate. Methods A total of 99 high-risk patients with benign prostatic hyperplasia undergoing transurethral resection of the prostate from April 2011 to February 2014 were enrolled in this study. The patients were divided into group 1 (tamsulosin and tolterodine, 35 cases) Group 2 (tamsulosin, 20) and Group 3 (tamsulosin or tolterodon not taken, 44). The days of postoperative hospital stay, the incidence of postoperative bladder spasm, the number of days and days of occurrence, the incidence of urinary incontinence after catheter removal, the number of days sustained and the number of daily occurrence were compared. Results All the 99 patients were operated successfully without any serious complications such as severe bleeding, bladder perforation and prostate resection syndrome. The number of postoperative hospital days in group 1, group 2, and group 3 was (8.8 ± 2.0), (10.2 ± 2.5), and (10.4 ± 2.5) days, respectively, and group 1 was significantly shorter than group 2 and group 3. The difference was statistically significant (P = 0.011). The duration of urge urinary incontinence and the number of daily occurrence after extubation were in group 1